CombiGene and CGT Catapult to develop epilepsy treatment

US approves first generic version of Sabril for epileptic patients
Credit: Chaikom

Swedish biotech CombiGene has signed an agreement with the UK’s CGT Catapult to develop manufacturing processes for a novel gene therapy aimed at treating epilepsy.

Specifically, the collaboration aims to develop a complete and final manufacturing process which will allow CombiGene to progress to commercial GMP production and thereafter clinical trials.

The biotech is pioneering a new therapy with the potential of dramatically improving the quality of life for a group of epilepsy patients for whom there currently is no effective treatment available.

CombiGene’s unique platform uses gene therapy vectors to deliver a combination of neuropeptide y (NPY) and NPY receptors into brain cells which has shown to inhibit epileptic seizures, in a series of preclinical studies.

CEO Jan Nilsson said: “CGT Catapult is highly renowned for its cutting-edge competence and state-of-the-art infrastructure for advanced therapeutic medicinal products.

“We evaluated several potential collaborators, and we could not have chosen a better partner.”

The second human expression study, initial data shows that the therapeutic genes encoded by CG01 are expressed in epileptic human tissue, thereby confirming that this method of administering genes encoded by the candidate drug is successful in human tissue.